Last reviewed · How we verify
citrate of caffeine
citrate of caffeine is a Central nervous system stimulant Small molecule drug developed by Assistance Publique Hopitaux De Marseille. It is currently in Phase 3 development for Treatment of apnea of prematurity.
Caffeine citrate acts as a central nervous system stimulant by inhibiting adenosine receptors.
Caffeine citrate acts as a central nervous system stimulant by inhibiting adenosine receptors. Used for Treatment of apnea of prematurity.
At a glance
| Generic name | citrate of caffeine |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | Central nervous system stimulant |
| Target | Adenosine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Caffeine citrate increases the activity of neurotransmitters such as dopamine and norepinephrine, leading to increased alertness and energy. This is achieved by blocking the action of adenosine, a chemical that promotes sleep and relaxation. As a result, caffeine citrate can help individuals feel more alert and awake.
Approved indications
- Treatment of apnea of prematurity
Common side effects
- Vomiting
- Diarrhea
- Abdominal distension
- Gasping
- Sleep disturbance
- Increased heart rate
- Increased blood pressure
- Seizure
- Withdrawal symptoms
Key clinical trials
- Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa (PHASE4)
- Improving Preterm Kidney Outcomes With Caffeine (PHASE2)
- Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support (PHASE2)
- Dose Optimization of Caffeine for HIE (PHASE1)
- CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO) (PHASE2)
- Caffeine Optimization for Oxygen Saturation Index in ELBW Infants (PHASE2)
- Caffeine Citrate in Preterm Infants at Risk of Apnea in Zambia (PHASE4)
- Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- citrate of caffeine CI brief — competitive landscape report
- citrate of caffeine updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI
Frequently asked questions about citrate of caffeine
What is citrate of caffeine?
How does citrate of caffeine work?
What is citrate of caffeine used for?
Who makes citrate of caffeine?
What drug class is citrate of caffeine in?
What development phase is citrate of caffeine in?
What are the side effects of citrate of caffeine?
What does citrate of caffeine target?
Related
- Drug class: All Central nervous system stimulant drugs
- Target: All drugs targeting Adenosine receptor
- Manufacturer: Assistance Publique Hopitaux De Marseille — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Treatment of apnea of prematurity